Skip to main content

Table 1 Demographic and clinical characteristics of all subjects at baseline

From: Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson’s disease

ParameterHCPDTDPIGDIndeterminate
Subjects, n50149705524
Age, years57.2 ± 5.4a64.0 ± 8.3b**64.0 ± 8.063.6 ± 8.365.0 ± 9.4
Male sex, n(%)25 (50)85 (57)43 (61)28 (51)14 (58)
Age at onset, years62.9 ± 8.563.1 ± 8.262.3 ± 8.563.8 ± 9.4
Disease duration, years1.1 ± 0.90.9 ± 0.71.3 ± 1.3d*1.2 ± 0.6c*
LEDD176.5 ± 135.3172.6 ± 133.3182.9 ± 142.4172.3 ± 129.2
MDS-UPDRS Part II: ADLs4.1 ± 3.23.7 ± 2.94.7 ± 3.54.0 ± 3.2
MDS-UPDRS Part III: Motor21.4 ± 9.321.1 ± 10.022.0 ± 9.520.7 ± 7.0
H&Y stage,1.8 ± 0.41.7 ± 0.41.9 ± 0.4d*1.9 ± 0.4c*
MMSE29.0 ± 1.326.8 ± 2.8b**27.0 ± 2.526.6 ± 3.427.0 ± 2.0
MoCA27.5 ± 2.025.1 ± 3.5b**25.3 ± 3.324.5 ± 3.625.6 ± 4.2
Plasma NfL, pg/ml8.8 ± 3.416.2 ± 7.6b**15.8 ± 7.015.8 ± 7.118.2 ± 10.3
  1. Abbreviations: PD Parkinson’s Disease; HC Healthy Control; TD Tremor-Dominant; PIGD Postural Instability Gait Disorder; LEDD Levodopa Equivalent Dose; MDS-UPDRS Movement Disorder Society Unified Parkinson’s Disease Rating Scale; ADL Activities of Daily Living; H&Y stage Hoehn and Yahr stage; MMSE Mini Mental State Examination; MoCA Montreal Cognitive Assessment; NfL Neurofilament light chain protein.a Continuous variables reported as mean ± standard deviation; Categorical variables reported as n (%)
  2. * P < 0.05, ** P < 0.01 using Analysis of variance for continuous variables; Chi-squared test for categorical variable for comparisons of variables between a PD and HC, c TD, PIGD and Indeterminate subtypes, d TD and PIGD subtypes